https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2024-10-28 / Mol Ther Oncol 2024 Dec;32(4):200899
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2024-10-28 / Mol Ther Oncol 2024 Dec;32(4):2008992024-10-28 00:00:002024-10-28 00:00:00IL-12 encoding oNDV synergizes with CAR-T cells in orthotopic models of non-small cell lung cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2024-09-13 / Oncol Lett 2024 Nov;28(5):550
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2024-09-13 / Oncol Lett 2024 Nov;28(5):5502024-09-13 00:00:002024-09-13 00:00:00induction of anti‑lung cancer immune response by the A549 lung cancer stem cell lysate‑sensitized dendritic cell vaccine
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2024-04-15 / Cell Rep Med 2024 May;5(5):101516
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2024-04-15 / Cell Rep Med 2024 May;5(5):1015162024-04-15 00:00:002025-02-25 12:30:45Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2024-02-10 / J Med Case Rep 2024 Feb;18(1):88
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2024-02-10 / J Med Case Rep 2024 Feb;18(1):882024-02-10 00:00:002024-02-10 00:00:00Dendritic cell vaccination in combination with erlotinib in a patient with inoperable lung adenocarcinoma: a case report
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-11-06 / Cureus 2023 Nov;15(11):e48412
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-11-06 / Cureus 2023 Nov;15(11):e484122023-11-06 00:00:002023-11-06 00:00:00Radioimmunotherapy With WT1 Dendritic Cell Vaccine for End-Stage Lung Adenocarcinoma Markedly Shrinks Tumors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-11-01 / Immun Inflamm Dis 2023 Nov;11(11):e1099
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-11-01 / Immun Inflamm Dis 2023 Nov;11(11):e10992023-11-01 00:00:002023-11-01 00:00:00The DC-T cell axis is an effective target for the treatment of non-small cell lung cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-10-19 / Cureus 2023 Oct;15(10):e47320
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-10-19 / Cureus 2023 Oct;15(10):e473202023-10-19 00:00:002023-10-19 00:00:00WT1 Dendritic Cell Vaccine Therapy Improves Immune Profile and Prolongs Progression-Free Survival in End-Stage Lung Cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-10-04 / Cells 2023 Oct;12(19)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-10-04 / Cells 2023 Oct;12(19)2023-10-04 00:00:002023-10-04 00:00:00Dendritic Cell Vaccination in Non-Small Cell Lung Cancer: Remodeling the Tumor Immune Microenvironment
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-02-01 / J Med Virol 2023 Feb;95(2):e28554
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-02-01 / J Med Virol 2023 Feb;95(2):e285542023-02-01 00:00:002023-02-01 00:00:00Tumor cell vaccine combined with Newcastle disease virus promote immunotherapy of lung cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-01-01 / Integr Cancer Ther 2022;21:15347354221083968
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-01-01 / Integr Cancer Ther 2022;21:153473542210839682022-01-01 00:00:002023-03-22 14:40:49A Single-Arm Phase II Study to Evaluate Efficacy and Safety of First-Line Treatment With DCVAC/LuCa, Standard of Care Chemotherapy and Shenqi Fuzheng Injection in Advanced (Stage IIIB/IV) Non-Small Cell Lung Cancer Patients
